

Adalimumab therapy for moderate to severe psoriasis: A trial

Journal of the American Academy of Dermatology
58, 106-115

DOI: [10.1016/j.jaad.2007.09.010](https://doi.org/10.1016/j.jaad.2007.09.010)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Archives of Dermatological Research, 2008, 300, 537-544.	1.1	45
2	From conventional to cutting edge: the new era of biologics in treatment of psoriasis. Dermatologic Therapy, 2008, 21, 131-141.	0.8	38
3	Adalimumab: a new alternative biologic agent for chronic plaque psoriasis. British Journal of Dermatology, 2008, 158, 435-436.	1.4	6
4	Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. British Journal of Dermatology, 2008, 159, 513-526.	1.4	182
5	Once weekly administration of etanercept 50mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. British Journal of Dermatology, 2008, 159, ???-???	1.4	149
6	Long-term data in the treatment of psoriasis. British Journal of Dermatology, 2008, 159, 18-24.	1.4	28
7	Adalimumab in dermatology. British Journal of Clinical Pharmacology, 2008, 66, 618-625.	1.1	33
8	Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study. Health and Quality of Life Outcomes, 2008, 6, 75.	1.0	40
9	Update on the Natural History and Systemic Treatment of Psoriasis. Advances in Dermatology, 2008, 24, 171-196.	2.0	33
10	Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2008, 58, 826-850.	0.6	1,128
11	National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. Journal of the American Academy of Dermatology, 2008, 59, 209-217.	0.6	157
12	Tratamiento de la psoriasis moderada y grave con adalimumab. Piel, 2008, 23, 577-581.	0.0	1
14	Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. Expert Opinion on Biological Therapy, 2008, 8, 363-370.	1.4	18
15	Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis. Dermatology, 2008, 216, 260-270.	0.9	104
16	Good clinical response to anti-psoriatic treatment with adalimumab and methotrexate does not inflict a direct effect on compartmentalization of T cell subsets: A pilot study. Journal of Dermatological Treatment, 2008, 19, 284-287.	1.1	4
18	Keynote lecture: psoriasis update. Expert Review of Dermatology, 2008, 3, S3-S9.	0.3	0
19	Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Yearbook of Dermatology and Dermatologic Surgery, 2008, 2008, 100-101.	0.0	0
21	Treating psoriasis with adalimumab. Therapeutics and Clinical Risk Management, 2008, Volume 4, 345-351.	0.9	33

#	ARTICLE	IF	CITATIONS
22	Emerging treatments in the management of psoriasis: biological targeting with ustekinumab. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2009, 2, 95.	0.8	0
23	Efalizumab: What Went Wrong?. <i>Psoriasis Forum</i> , 2009, 15a, 54-56.	0.1	0
24	Biologics in the management of psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2009, 2, 111.	0.8	8
25	Can Adalimumab Make a Smooth and Easy Transition from Cyclosporine a Reality? A Case Series of Successful Transitions. <i>Psoriasis Forum</i> , 2009, 15a, 33-35.	0.1	6
26	Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. <i>Biologics: Targets and Therapy</i> , 2009, , 303.	3.0	5
27	Cost-effectiveness of biologics for moderate-to-severe psoriasis from the perspective of the Swiss healthcare system. <i>European Journal of Dermatology</i> , 2009, 19, 494-499.	0.3	15
28	A Mechanism-Based Classification of Dermatologic Reactions to Biologic Agents Used in the Treatment of Cutaneous Disease: Part 1. <i>Dermatitis</i> , 2009, 20, 182-192.	0.8	9
29	Ustekinumab for the treatment of plaque psoriasis. <i>Expert Review of Dermatology</i> , 2009, 4, 443-453.	0.3	1
30	Pityriasis Rubra Pilaris Responding Rapidly to Adalimumab. <i>Archives of Dermatology</i> , 2009, 145, 99-101.	1.7	32
31	Efalizumab discontinuation: A practical strategy. <i>Journal of Dermatological Treatment</i> , 2009, 20, 132-136.	1.1	35
32	Management of Severe Psoriasis with TNF Antagonists. <i>Current Problems in Dermatology</i> , 2009, 38, 107-136.	0.8	22
33	Marked Improvement in Nail Psoriasis during Treatment with Adalimumab. <i>Dermatology</i> , 2009, 219, 353-356.	0.9	15
34	A Multicenter Open-Label Experience on the Response of Psoriasis to Adalimumab and Effect of Dose Escalation in Non-Responders: The Aphrodite Project. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 227-233.	1.0	10
35	Efficacy of Systemic Treatments for Moderate to Severe Plaque Psoriasis: Systematic Review and Meta-Analysis. <i>Dermatology</i> , 2009, 219, 209-218.	0.9	87
38	Biologics in the Treatment of Psoriasis: Clinical and Economic Overview. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, S49-S57.	0.6	22
39	Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2009, 13, S58-S66.	0.6	19
41	Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis. <i>International Journal of Dermatology</i> , 2009, 48, 653-658.	0.5	19
42	Treatment of acrodermatitis continua of Hallopeau with adalimumab. <i>British Journal of Dermatology</i> , 2009, 160, 203-205.	1.4	26

#	ARTICLE	IF	CITATIONS
43	Economic evaluation of systemic therapies for moderate to severe psoriasis. <i>British Journal of Dermatology</i> , 2009, 160, 1264-1272.	1.4	73
44	British Association of Dermatologists's™ guidelines for biologic interventions for psoriasis 2009. <i>British Journal of Dermatology</i> , 2009, 161, 987-1019.	1.4	412
45	Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 784-788.	0.6	26
46	Long-term efficacy of biologics in dermatology. <i>Dermatologic Therapy</i> , 2009, 22, 22-33.	0.8	28
47	Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?. <i>Dermatologic Therapy</i> , 2009, 22, 431-440.	0.8	40
48	European S3€Guidelines on the systemic treatment of psoriasis vulgaris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2009, 23, 1-70.	1.3	683
49	Emerging drugs for psoriasis. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 145-163.	1.0	7
50	Documento de consenso sobre la evaluaci3n y el tratamiento de la psoriasis moderada/grave del Grupo Espaol de Psoriasis de la Academia Espaola de DermatologAa y VenereologAa. <i>Actas Dermo-sifiliogrAificas</i> , 2009, 100, 277-286.	0.2	95
51	Directrices espaolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biol3gicos. <i>Actas Dermo-sifiliogrAificas</i> , 2009, 100, 386-413.	0.2	73
52	Eficiencia de los agentes biol3gicos en el tratamiento de la psoriasis moderada-grave. <i>Actas Dermo-sifiliogrAificas</i> , 2009, 100, 792-803.	0.2	19
53	A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, S1-S46.	0.6	35
55	Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent. , 2009, , 229-254.		4
56	Consensus Document on the Evaluation and Treatment of Moderate to Severe Psoriasis. Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Actas Dermo-sifiliogrAificas</i> , 2009, 100, 277-288.	0.2	11
57	Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents. <i>Actas Dermo-sifiliogrAificas</i> , 2009, 100, 386-413.	0.2	14
58	Efficiency of Biologic Agents in the Treatment of Moderate to Severe Psoriasis. <i>Actas Dermo-sifiliogrAificas</i> , 2009, 100, 792-803.	0.2	4
59	Ustekinumab. <i>Drugs</i> , 2009, 69, 1141-1152.	4.9	30
60	Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report. <i>Journal of Medical Case Reports</i> , 2009, 3, 8573.	0.4	26
61	Adalimumab: a guide to its use in plaque psoriasis. <i>Drugs and Therapy Perspectives</i> , 2009, 25, 6-9.	0.3	0

#	ARTICLE	IF	CITATIONS
62	Adalimumab. American Journal of Clinical Dermatology, 2009, 10, 43-50.	3.3	14
63	Evaluation and Management of Psoriasis: An Internist's Guide. Medical Clinics of North America, 2009, 93, 1291-1303.	1.1	50
65	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. Yearbook of Dermatology and Dermatologic Surgery, 2009, 2009, 142-143.	0.0	0
66	Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Yearbook of Dermatology and Dermatologic Surgery, 2009, 2009, 143-145.	0.0	0
67	The Use of Biologics for Psoriasis in Asia-Pacific Region. Current Rheumatology Reviews, 2009, 5, 149-152.	0.4	5
68	EADV preceptorship: advances in dermatology. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 2-24.	1.3	11
69	Comparing biological therapies in psoriasis: implications for clinical practice. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 10-14.	1.3	26
70	Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. British Journal of Pharmacology, 2010, 160, 810-820.	2.7	120
71	Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study. Journal of Dermatology, 2010, 37, 299-310.	0.6	169
72	Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001-2006. British Journal of Dermatology, 2010, 162, 384-389.	1.4	34
73	Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement. British Journal of Dermatology, 2010, 162, 1216-1223.	1.4	31
74	Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. British Journal of Dermatology, 2010, 162, 1349-1358.	1.4	39
75	A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. British Journal of Dermatology, 2010, 163, 402-411.	1.4	99
76	Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study. British Journal of Dermatology, 2010, 163, 889-892.	1.4	21
77	Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. British Journal of Dermatology, 2010, 163, 838-846.	1.4	45
78	Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. British Journal of Dermatology, 2010, 163, 859-862.	1.4	23
79	Pityriasis rubra pilaris successfully treated with adalimumab. Clinical and Experimental Dermatology, 2010, 35, 792-793.	0.6	21
80	Multiple cutaneous malignancies arising in a patient with Crohn disease treated with concomitant azathioprine and antitumour necrosis factor- α . Clinical and Experimental Dermatology, 2010, 35, 793-795.	0.6	7

#	ARTICLE	IF	CITATIONS
81	Update of the management of chronic psoriasis: new approaches and emerging treatment options. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2010, 3, 25.	0.8	4
82	How Long Does the Benefit of Biologics Last? An Update on Time to Relapse and Potential for Rebound of Biologic Agents for Psoriasis. <i>Psoriasis Forum</i> , 2010, 16a, 36-42.	0.1	22
84	Guidelines on the Management of Psoriasis in South Africa. <i>South African Medical Journal</i> , 2010, 100, 255.	0.2	19
85	Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. <i>Core Evidence</i> , 2010, 5, 11.	4.7	11
86	The psoriasiform reaction pattern. , 2010, , 71-91.e18.		4
87	Strategies for Treatment With Anti-Tumor Necrosis Factor Agents in Psoriasis. <i>Archives of Dermatology</i> , 2010, 146, 186-8.	1.7	3
88	Updated Turkish Guidelines for the Management of Psoriasis with Biologic Agents. <i>Turkderm</i> , 2010, 44, 105-112.	0.0	7
89	Psoriasis Care: New and Emerging Pharmacologic Trends. <i>Journal of Cutaneous Medicine and Surgery</i> , 2010, 14, 119-129.	0.6	8
90	Cost-Effectiveness of Biological Therapy in Remission Induction of Moderate to Severe Plaque Psoriasis. <i>Dermatology</i> , 2010, 221, 236-242.	0.9	21
91	Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis. <i>Archives of Dermatology</i> , 2010, 146, 127-32.	1.7	137
92	Impact of Adalimumab on Symptoms of Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis: A Pooled Analysis of Randomized Clinical Trials. <i>Dermatology</i> , 2010, 220, 1-7.	0.9	20
93	The Impact of Methodological Approaches for Presenting Long-Term Clinical Data on Estimates of Efficacy in Psoriasis Illustrated by Three-Year Treatment Data on Infliximab. <i>Dermatology</i> , 2010, 221, 43-47.	0.9	96
95	Psoriasis and its treatment with adalimumab. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 133-152.	1.4	5
96	The therapeutic potential of TNF- α antagonists for skin psoriasis comorbidities. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 1197-1208.	1.4	19
97	Treatment of Scalp Psoriasis: Review of the Evidence and Delphi Consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology. <i>Actas Dermo-sifiligráficas</i> , 2010, 101, 827-846.	0.2	6
98	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2010, 36, 1185-1206.	3.1	444
99	Goeckerman therapy versus biologics in the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 516-517.	0.6	2
100	Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 228-234.	0.6	46

#	ARTICLE	IF	CITATIONS
101	Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 448-456.	0.6	144
102	Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 1058-1069.	0.6	102
103	Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 571-579.	0.6	115
104	A new era in the management of psoriasis? The biologics: facts and controversies. <i>Clinics in Dermatology</i> , 2010, 28, 81-87.	0.8	30
105	Safety and Efficacy of the Tumor Necrosis Factor Antagonists. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 35-47.	1.6	36
106	Tratamiento de la psoriasis del cuero cabelludo. Revisi3n de la evidencia y Consenso Delphi del Grupo de Psoriasis de la Academia Espa±ola de DermatologÅa y VenereologÅa. <i>Actas Dermo-sifiliogrÅficas</i> , 2010, 101, 827-846.	0.2	13
107	Coronary Heart Disease and Stroke Risk in Patients with Psoriasis: Retrospective Analysis. <i>American Journal of Medicine</i> , 2010, 123, 350-357.	0.6	92
108	Comparative Effectiveness Without Head-to-Head Trials. <i>Pharmacoeconomics</i> , 2010, 28, 935-945.	1.7	247
109	The Latest Advances in Pharmacogenetics and Pharmacogenomics in the Treatment of Psoriasis. <i>Molecular Diagnosis and Therapy</i> , 2010, 14, 81-93.	1.6	29
110	Advances in the treatment of moderate-to-severe plaque psoriasis. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 795-806.	0.5	27
111	Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 51-62.	3.3	52
112	Quality of Life in Patients with Immune-Mediated Inflammatory Diseases. <i>Journal of rheumatology Supplement, The</i> , 2011, 88, 7-19.	2.2	20
114	Narrowband UV-B, Monochromatic Excimer Laser, and Photodynamic Therapy in Psoriasis: A Consensus Statement of the Spanish Psoriasis Group. <i>Actas Dermo-sifiliogrÅficas</i> , 2011, 102, 175-186.	0.2	4
115	Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis. <i>ReumatologÅa ClÅnica (English Edition)</i> , 2011, 7, 179-188.	0.2	8
117	Effects of Adalimumab versus Placebo on Risk of Symptom Worsening in Psoriasis and Subsequent Impacts on Health-Related Quality-of-Life. <i>Clinical Drug Investigation</i> , 2011, 31, 51-60.	1.1	13
118	The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 321-337.	3.3	62
120	Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 671-681.	0.6	69
121	The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A±systematic review and meta-analysis of randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 1035-1050.	0.6	197

#	ARTICLE	IF	CITATIONS
122	Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2011, 165, 661-668.	1.4	128
123	Adverse effects of biologics: a network meta-analysis and Cochrane overview. <i>The Cochrane Library</i> , 2016, 2016, CD008794.	1.5	481
124	Treatment of Psoriasis in the Setting of Excessive Alcohol Intake: From the Medical Board of the National Psoriasis Foundation. <i>Psoriasis Forum</i> , 2011, 17a, 119-130.	0.1	0
125	Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. <i>Drug Design, Development and Therapy</i> , 2011, 5, 41.	2.0	18
126	Efficacy and Safety of a Second Adalimumab Treatment Cycle in Psoriasis Patients who Relapsed after Adalimumab Discontinuation or Dosage Reduction: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Psoriasis Forum</i> , 2011, 17a, 88-96.	0.1	6
127	Psoriatic Eye Manifestations. <i>Psoriasis Forum</i> , 2011, 17a, 169-179.	0.1	11
128	Care of Generalized Psoriasis in Elderly Patients beyond Topical Therapy: A Review and a Proposed Algorithm. <i>Psoriasis Forum</i> , 2011, 17a, 105-116.	0.1	0
130	Use of pharmacogenomics in psoriasis. <i>Clinical Investigation</i> , 2011, 1, 399-411.	0.0	4
131	Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1318-1327.	1.9	177
132	Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. <i>British Journal of Dermatology</i> , 2011, 164, 434-441.	1.4	98
133	Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. <i>British Journal of Dermatology</i> , 2011, 165, 640-645.	1.4	51
134	Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. <i>British Journal of Dermatology</i> , 2011, 165, 652-660.	1.4	120
135	Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1012-1020.	1.3	47
136	311-nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2011, 27, 186-189.	0.7	42
137	S3 - Guidelines on the treatment of psoriasis vulgaris Update 2011. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, S1-S95.	0.4	66
139	Tratamientos biológicos y cáncer. <i>Piel</i> , 2011, 26, 231-235.	0.0	0
140	Ajuste de dosis en psoriasis tratadas con adalimumab. <i>Piel</i> , 2011, 26, 358-360.	0.0	2
141	Anti-cytokine therapies for psoriasis. <i>Experimental Cell Research</i> , 2011, 317, 1293-1300.	1.2	51

#	ARTICLE	IF	CITATIONS
142	Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin. <i>BMC Dermatology</i> , 2011, 11, 5.	2.1	20
143	Pharmacogenetics of psoriasis. <i>Pharmacogenomics</i> , 2011, 12, 87-101.	0.6	24
144	Anti-tumor necrosis factor- α therapies for immune-mediated and inflammatory skin diseases. <i>Drug Development Research</i> , 2011, 72, 615-622.	1.4	1
145	Topical Psoriasis Therapy in the Age of Biologics: Evidence-Based Treatment Recommendations. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011, 15, 309-321.	0.6	11
146	A Refresher on Herpes Zoster, Current Status on Vaccination, and the Role of the Dermatologist. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011, 15, 185-191.	0.6	4
147	Focus on skin cancer association and progression under TNF antagonist therapy. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1215-1222.	1.4	6
148	Canadian Guidelines for the Management of Plaque Psoriasis: Overview. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011, 15, 210-219.	0.6	76
149	Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 864-71.	3.8	259
150	Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series. <i>Journal of Dermatological Treatment</i> , 2011, 22, 75-78.	1.1	14
151	Weight-Based Adaptation of TNF-Antagonist Induction versus Maintenance Dose. <i>Case Reports in Dermatology</i> , 2011, 3, 124-129.	0.3	3
152	Management of psoriatic arthritis from the view of the dermatologist. <i>Nature Reviews Rheumatology</i> , 2011, 7, 588-598.	3.5	45
153	Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. <i>Journal of Dermatological Treatment</i> , 2011, 22, 65-74.	1.1	32
154	Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet. <i>Archives of Dermatology</i> , 2011, 147, 429.	1.7	96
155	Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders. <i>Journal of Dermatological Treatment</i> , 2011, 22, 90-101.	1.1	9
156	A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis. <i>Journal of Investigative Dermatology</i> , 2012, 132, 304-314.	0.3	157
157	Putting together the psoriasis puzzle: an update on developing targeted therapies. <i>DMM Disease Models and Mechanisms</i> , 2012, 5, 423-433.	1.2	111
158	Exploring Priority Research Areas in Psoriasis and Psoriatic Arthritis from Dermatologists's™ Perspective: A Report from the GRAPPA 2011 Annual Meeting. <i>Journal of Rheumatology</i> , 2012, 39, 2204-2210.	1.0	3
159	Psoriasis Vulgarisli Hastalarda Etanercept, Ä°nfliksimab ve AdalimumabÄ±n Etki ve Yan Etkilerinin KarÄ±laÅtÄ±rÄ±lmasÄ±. <i>Turkderm</i> , 2012, 46, 11-14.	0.0	0

#	ARTICLE	IF	CITATIONS
160	Perniosis Induced by a Cold-Therapy System. Archives of Dermatology, 2012, 148, 1101.	1.7	9
161	Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis. Archives of Dermatology, 2012, 148, 1244.	1.7	255
162	Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. European Journal of Dermatology, 2012, 22, 762-769.	0.3	25
163	Biologic Therapy in Psoriasis: Perspectives on Associated Risks and Patient Management. Journal of Cutaneous Medicine and Surgery, 2012, 16, 153-168.	0.6	26
164	Efficacy, safety and medication cost implications of adalimumab 40mg weekly dosing in patients with psoriasis with suboptimal response to 40mg every other week dosing: results from an open-label study. British Journal of Dermatology, 2012, 167, 658-667.	1.4	44
165	Placebo response in relation to clinical trial design: a systematic review and meta-analysis of randomized controlled trials for determining biologic efficacy in psoriasis treatment. Archives of Dermatological Research, 2012, 304, 707-717.	1.1	24
166	Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses. Dermatology and Therapy, 2012, 2, 9.	1.4	29
167	Nonserious Infections. Rheumatic Disease Clinics of North America, 2012, 38, 707-725.	0.8	16
169	Therapy for Spondyloarthritis. Rheumatic Disease Clinics of North America, 2012, 38, 583-600.	0.8	8
170	A Prospective, Randomized, Placebo-Controlled Study to Identify Biomarkers Associated with Active Treatment in Psoriatic Arthritis: Effects of Adalimumab Treatment on Lesional and Nonlesional Skin. Dermatology, 2012, 225, 298-303.	0.9	13
171	Efficacy of adalimumab in the treatment of psoriasis: A retrospective study of 15 patients in daily practice. Journal of Dermatological Treatment, 2012, 23, 203-207.	1.1	25
172	A Subset of Methylated CpG Sites Differentiate Psoriatic from Normal Skin. Journal of Investigative Dermatology, 2012, 132, 583-592.	0.3	138
173	Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. Journal of the American Academy of Dermatology, 2012, 66, e33-e45.	0.6	89
174	The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. Journal of the American Academy of Dermatology, 2012, 66, e67-e76.	0.6	62
175	Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. Journal of the American Academy of Dermatology, 2012, 66, 241-251.	0.6	157
176	Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 2012, 66, 369-375.	0.6	158
177	Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. Journal of the American Academy of Dermatology, 2012, 66, 376-386.	0.6	40
178	Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. Journal of the American Academy of Dermatology, 2012, 66, 731-741.	0.6	101

#	ARTICLE	IF	CITATIONS
179	Comparison of Ustekinumab With Other Biological Agents for the Treatment of Moderate to Severe Plaque Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 1403.	1.7	64
180	Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIb trial. <i>British Journal of Dermatology</i> , 2012, 167, 1374-1381.	1.4	59
181	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. <i>British Journal of Dermatology</i> , 2012, 166, 861-872.	1.4	121
182	Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. <i>British Journal of Dermatology</i> , 2012, 167, 3-11.	1.4	85
183	Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2012, 167, 12-20.	1.4	38
184	Current and Emerging Systemic Treatment Strategies for Psoriasis. <i>Drugs</i> , 2012, 72, 1867-1880.	4.9	35
185	Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients. <i>Chest</i> , 2012, 142, e1S-e111S.	0.4	52
186	A Review of Health Outcomes in Patients with Psoriasis. <i>Dermatologic Clinics</i> , 2012, 30, 61-72.	1.0	28
187	Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 1349-1361.	0.6	40
188	IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 145-154.e9.	1.5	320
189	Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research. <i>Value in Health</i> , 2012, 15, 940-947.	0.1	290
190	Cost Per Responder Associated with Biologic Therapies for Crohn's Disease, Psoriasis, and Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2012, 29, 620-634.	1.3	56
192	Emerging Adverse Cutaneous Drug Reactions. <i>Dermatologic Clinics</i> , 2012, 30, 695-730.	1.0	4
193	Consensus Guidelines for the Management of Plaque Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 95.	1.7	148
194	Comparative Efficacy of Biologics in Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 365-374.	3.3	52
195	Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy. <i>PLoS ONE</i> , 2012, 7, e33486.	1.1	92
196	Ustekinumab Improves Psoriasis without Altering T Cell Cytokine Production, Differentiation, and T Cell Receptor Repertoire Diversity. <i>PLoS ONE</i> , 2012, 7, e51819.	1.1	22
197	The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents. <i>Open Access Rheumatology: Research and Reviews</i> , 2012, 4, 33.	0.8	4

#	ARTICLE	IF	CITATIONS
198	Biologics in the treatment of psoriasis and emerging new therapies in the pipeline. <i>Psoriasis: Targets and Therapy</i> , 2012, , 29.	1.2	2
199	Psoriasis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2012, 7, 385-422.	9.6	412
200	Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. <i>European Journal of Health Economics</i> , 2012, 13, 145-156.	1.4	17
201	Management of moderate to severe psoriasis with systemic immunomodulatory therapies: a 5-year experience from two departments of dermatology of Northern France. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1038-1039.	1.3	1
202	The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 991-998.	1.3	17
203	Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1007-1013.	1.3	14
204	Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 1298-1303.	1.3	13
205	Cost-effectiveness of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 768-777.	1.3	31
206	The concept of psoriasis as a systemic inflammation: implications for disease management. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 3-11.	1.3	253
207	Implementing treatment goals for successful long-term management of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 12-20.	1.3	70
208	Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 21-29.	1.3	21
209	Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2012, 166, 179-188.	1.4	177
210	S3 " Guidelines on the treatment of psoriasis vulgaris (English version). Update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, S1-95.	0.4	235
211	Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: Results in a single community-based hospital. <i>Journal of Dermatology</i> , 2012, 39, 265-268.	0.6	14
212	Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. <i>British Journal of Dermatology</i> , 2012, 167, 417-423.	1.4	42
213	Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab ² certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. <i>British Journal of Dermatology</i> , 2012, 167, 180-190.	1.4	131
214	Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. <i>British Journal of Dermatology</i> , 2012, 167, 643-648.	1.4	31
215	German S3-guidelines on the treatment of psoriasis vulgaris (short version). <i>Archives of Dermatological Research</i> , 2012, 304, 87-113.	1.1	96

#	ARTICLE	IF	CITATIONS
216	Etanercept use for psoriasis in Taiwan: a case series study. <i>International Journal of Dermatology</i> , 2013, 52, 673-680.	0.5	7
217	Patient preferences for psoriasis treatments: impact of treatment experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 187-198.	1.3	55
218	Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 593-600.	1.3	32
219	Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 634-642.	1.3	46
220	An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1444-1447.	1.3	14
221	A randomized, head-to-head pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 899-906.	1.3	34
222	Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions. <i>JAMA Internal Medicine</i> , 2013, 173, 1416.	2.6	129
223	Analysis of 10 years drug lifecycle management (LCM) activities in the Japanese market. <i>Drug Discovery Today</i> , 2013, 18, 1109-1116.	3.2	8
224	Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. <i>British Journal of Dermatology</i> , 2013, 169, 306-313.	1.4	65
225	Cost Effectiveness of Biologic Therapies for Plaque Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 315-326.	3.3	55
226	Biologic Therapies in the Treatment of Psoriasis: A Comprehensive Evidence-Based Basic Science and Clinical Review and a Practical Guide to Tuberculosis Monitoring. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 44, 121-140.	2.9	69
227	Psoriasis, Anti-Tumor Necrosis Factor Therapy, and Tuberculosis: Report of Three Challenging Cases and Literature Review. <i>Infectious Diseases and Therapy</i> , 2013, 2, 59-73.	1.8	10
228	Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents. <i>BioDrugs</i> , 2013, 27, 359-373.	2.2	26
230	Biological therapies for psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1715-1730.	1.4	23
231	Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients. <i>BMC Genomics</i> , 2013, 14, 527.	1.2	108
232	IL-17, IL-22 and Their Producing Cells: Role in Inflammation and Autoimmunity. , 2013, , .		1
233	Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. <i>Journal of Dermatological Treatment</i> , 2013, 24, 351-355.	1.1	17
234	Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1325-1334.	1.4	9

#	ARTICLE	IF	CITATIONS
235	The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. <i>Trends in Immunology</i> , 2013, 34, 174-181.	2.9	399
236	Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 165-178.	0.5	315
237	Immunogenicidad en terapia biol3gica. Implicaciones en Dermatolog3a. <i>Actas Dermo-sifiliogr3ficas</i> , 2013, 104, 471-479.	0.2	33
239	Spanish Evidence-Based Guidelines on the Treatment of Psoriasis With Biologic Agents, 2013. Part 1: On Efficacy and Choice of Treatment. <i>Actas Dermo-sifiliogr3ficas</i> , 2013, 104, 694-709.	0.2	32
240	Immunogenicity in Biologic Therapy: Implications for Dermatology. <i>Actas Dermo-sifiliogr3ficas</i> , 2013, 104, 471-479.	0.2	13
241	Association of gender, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 650-651.	0.6	20
242	Biologic systemic therapy for moderate-to-severe psoriasis: A review. <i>Journal of Taibah University Medical Sciences</i> , 2013, 8, 142-150.	0.5	4
243	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. <i>British Journal of Dermatology</i> , 2013, 168, 402-411.	1.4	118
244	An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. <i>British Journal of Dermatology</i> , 2013, 168, 374-380.	1.4	16
245	Novel colloidal carriers for psoriasis: Current issues, mechanistic insight and novel delivery approaches. <i>Journal of Controlled Release</i> , 2013, 170, 380-395.	4.8	139
246	Biological treatments for moderate-to-severe psoriasis: indirect comparison. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 121-130.	0.7	37
247	Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 949-958.	1.3	56
248	Immunogenicity of anti-TNF± therapy in psoriasis: a clinical issue?. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1673-1682.	1.4	56
249	Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice. <i>Journal of Dermatological Treatment</i> , 2013, 24, 361-368.	1.1	29
250	Treatment of Psoriasis and Psoriatic Arthritis. <i>BioDrugs</i> , 2013, 27, 3-12.	2.2	42
251	A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. <i>British Journal of Dermatology</i> , 2013, 168, 1080-1087.	1.4	77
252	Which Antipsoriatic Drug Has the Fastest Onset of Action?â€”Systematic Review on the Rapidity of the Onset of Action. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1963-1970.	0.3	57
253	Effects of the Tumor Necrosis Factor-± Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 83-90.	1.3	72

#	ARTICLE	IF	CITATIONS
254	Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. <i>British Journal of Dermatology</i> , 2013, 169, 1141-1147.	1.4	46
255	Drug survival rates in patients with psoriasis after treatment with biologics. <i>Journal of Dermatology</i> , 2013, 40, 1008-1013.	0.6	67
257	Injection site reactions of adalimumab spreading on the trunk in a psoriatic arthritis patient. <i>Journal of Dermatology</i> , 2013, 40, 931-932.	0.6	3
258	Biologic therapy for psoriasis: early response implies future success. <i>British Journal of Dermatology</i> , 2013, 169, 1178-1179.	1.4	1
259	Superficial Frostbite Masquerading as Ecchymosis from Improper Cryotherapy Use After Q-Switched Laser Tattoo Treatment. <i>Dermatologic Surgery</i> , 2013, 39, 474-476.	0.4	0
260	Generalized erythroderma and palmoplantar hyperkeratosis in a patient receiving <sc>TNF</sc>â€alpha antagonist therapy. <i>Journal of Cutaneous Pathology</i> , 2013, 40, 855-856.	0.7	5
261	The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials. <i>British Journal of Dermatology</i> , 2013, 169, 1198-1206.	1.4	15
262	<sc>TNFÎ±</sc>â€and <sc>IL</sc>â€17Aâ€mediated S100<sc>A</sc>8 expression is regulated by p38 <sc>MAPK</sc>. <i>Experimental Dermatology</i> , 2013, 22, 476-481.	1.4	34
263	Successful treatment of psoriasis with interrupted adalimumab use: A case report. <i>Journal of Dermatology</i> , 2013, 40, 477-478.	0.6	0
264	Incomplete Data in Randomized Dermatology Trials: Consequences and Statistical Methodology. <i>Dermatology</i> , 2013, 226, 19-27.	0.9	6
265	Clinical Trial Simulation to Inform Phase 2: Comparison of Concentrated vs. Distributed Firstâ€inâ€Patient Study Designs in Psoriasis. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-9.	1.3	11
266	Immunotargeting in the management of psoriasis. <i>ImmunoTargets and Therapy</i> , 2013, 2, 51.	2.7	2
267	Efficacy and safety of biologics in the treatment of moderate to severe psoriasis: a comprehensive meta-analysis of randomized controlled trials. <i>Cadernos De Saude Publica</i> , 2013, 29, s17-s31.	0.4	4
268	Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab. <i>Annals of Dermatology</i> , 2013, 25, 496.	0.3	2
269	Promising New Treatments for Psoriasis. <i>Scientific World Journal, The</i> , 2013, 2013, 1-9.	0.8	43
270	Systemic Lupus Erythematosus and Psoriasis: Comparison of Immunopathogenesis. <i>Psoriasis Forum</i> , 2013, 19a, 165-175.	0.1	1
271	Tumor Necrosis Factor-Î± Triad: Psoriasis, Cardiovascular Disease, and Depression. <i>Psoriasis Forum</i> , 2013, 19a, 41-49.	0.1	3
272	Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis: A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle. <i>BioMed Research International</i> , 2014, 1-10.	0.9	24

#	ARTICLE	IF	CITATIONS
273	Immunobiologics: Intermittent versus Continuous Use in the Treatment of Moderate to Severe Psoriasis. <i>Psoriasis Forum</i> , 2014, 20a, 49-54.	0.1	0
274	Tuberculosis Reactivation Risk in Dermatology. <i>Journal of rheumatology Supplement, The</i> , 2014, 91, 65-70.	2.2	9
275	Induction or Exacerbation of Psoriasis in Patients with Crohn's Disease under Treatment with Anti-TNF Antibodies. <i>Digestion</i> , 2014, 89, 209-215.	1.2	18
276	â€˜Happyâ€™™ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. <i>British Journal of Dermatology</i> , 2014, 171, 1189-1196.	1.4	89
277	Unmet needs in the treatment of psoriasis. <i>European Journal of Dermatology</i> , 2014, 24, 523-532.	0.3	24
278	Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 11-32.	1.0	50
279	Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1016-1024.	1.3	39
280	Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1701-1706.	1.3	13
281	Disease Control for Patients with Psoriasis Receiving Continuous Versus Interrupted Therapy with Adalimumab or Etanercept: A Clinical Practice Study. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 543-549.	3.3	9
282	First-in-human trial of nanoelectroablation therapy for basal cell carcinoma: proof of method. <i>Experimental Dermatology</i> , 2014, 23, 135-137.	1.4	95
283	The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 846-852.	1.3	58
284	Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 882-890.	1.3	36
285	Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). <i>British Journal of Dermatology</i> , 2014, 171, 137-147.	1.4	104
286	Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1633-1653.	1.3	65
287	Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 467-478.	3.3	48
288	Appearance of de novo dysplastic spitzoid compound naevus in an adalimumab-treated psoriatic patient: Case report and review of the possible causal relationship with TNF± blockers. <i>Australasian Journal of Dermatology</i> , 2014, 55, 156-157.	0.4	3
289	Biologic fatigue in psoriasis. <i>Journal of Dermatological Treatment</i> , 2014, 25, 78-82.	1.1	65
290	TNF-induced leukocyte-endothelial cell interactions show marked interindividual differences independent of the clinical response to adalimumab. <i>Experimental Dermatology</i> , 2014, 23, 133-135.	1.4	6

#	ARTICLE	IF	CITATIONS
291	Early tissue responses in psoriasis to the antitumour necrosis factor- β biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. <i>British Journal of Dermatology</i> , 2014, 171, 97-107.	1.4	45
292	The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. <i>International Journal of Dermatology</i> , 2014, 53, 714-722.	0.5	53
293	Network Meta-analysis of Treatments for Chronic Plaque Psoriasis in Canada. <i>Journal of Cutaneous Medicine and Surgery</i> , 2014, 18, 371-378.	0.6	14
294	Biologic Agents for Moderate-to-Severe Plaque Psoriasis. <i>Journal of the Dermatology Nurses' Association</i> , 2014, 6, S12-S30.	0.1	0
295	Current and potential immune therapies and vaccines in the management of psoriasis. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 876-886.	1.4	6
296	Biologic Agents for Moderate-to-Severe Plaque Psoriasis. <i>Journal of the Dermatology Nurses' Association</i> , 2014, 6, 178-196.	0.1	0
297	Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis. <i>Psoriasis: Targets and Therapy</i> , 0, , 11.	1.2	0
298	Serum Levels of TNF- α , IL-12/23p40, and IL-17 in Plaque Psoriasis and Their Correlation with Disease Severity. <i>Journal of Immunology Research</i> , 2014, 2014, 1-9.	0.9	55
299	Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2014, 150, 130.	2.0	76
300	JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis. <i>Journal of Immunology Research</i> , 2014, 2014, 1-7.	0.9	102
301	Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 333-337.	1.3	217
302	Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 484-492.	0.6	88
303	Reacciones psoriasiformes paradójicas durante el tratamiento con terapia anti-factor de necrosis tumoral. Manejo clínico. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 752-761.	0.2	28
304	Efficacy and safety of systemic treatments for moderate to severe psoriasis: meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2014, 170, 274-303.	1.4	141
305	Health-Related Quality of Life Worsens Disproportionately to Objective Signs of Psoriasis After Withdrawal of Adalimumab Therapy. <i>Dermatology and Therapy</i> , 2014, 4, 33-42.	1.4	13
306	Cost-effectiveness of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system. <i>International Journal of Dermatology</i> , 2014, 53, 1151-1156.	0.5	13
307	Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 922-929.	1.4	35
308	Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: a retrospective study of 30 patients in daily practice. <i>European Journal of Dermatology</i> , 2014, 24, 217-223.	0.3	17

#	ARTICLE	IF	CITATIONS
309	Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1424-1430.	1.3	57
310	Clinical Management of Paradoxical Psoriasiform Reactions During TNF- α Therapy. Actas Dermo-sifiligráficas, 2014, 105, 752-761.	0.2	9
311	Psoriasis. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a015354-a015354.	2.9	233
312	Antidrug antibodies in psoriasis: a systematic review. British Journal of Dermatology, 2014, 170, 261-273.	1.4	143
314	Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Annals of Medicine, 2014, 46, 547-554.	1.5	93
315	Drug therapies in dermatology. Clinical Medicine, 2014, 14, 47-53.	0.8	7
316	Ustekinumab Induces Fast Response and Maintenance of Very Severe Refractory Scalp Psoriasis: Results in Two Greek Patients from the Psoriasis Hospital-Based Clinic. Dermatology, 2014, 228, 107-111.	0.9	16
317	Foreword. American Journal of Clinical Dermatology, 2014, 15, 3-4.	3.3	0
318	Effect of adalimumab on sleep parameters in patients with psoriasis and obstructive sleep apnea: a randomized controlled trial. Journal of Dermatological Treatment, 2014, 25, 57-60.	1.1	29
319	The risk of deep fungal infections during biologic therapy for psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 1277-1285.	1.3	7
320	Estudio retrospectivo de la eficacia y seguridad de adalimumab en el tratamiento de la psoriasis en la práctica clínica diaria. Piel, 2014, 29, 468-476.	0.0	0
321	Advances in treating psoriasis. F1000prime Reports, 2014, 6, 4.	5.9	58
323	Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). British Journal of Dermatology, 2015, 173, 777-787.	1.4	67
324	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. British Journal of Dermatology, 2015, 173, 949-961.	1.4	253
325	Increased serum resistin levels correlate with psoriasis: a meta-analysis. Lipids in Health and Disease, 2015, 14, 44.	1.2	26
326	Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. British Journal of Dermatology, 2015, 173, 510-518.	1.4	87
327	Cytotoxicity and genotoxicity of intravitreal adalimumab administration in rabbit retinal cells. Arquivos Brasileiros De Oftalmologia, 2015, 78, 89-93.	0.2	9
328	Analytical Assessment of TNF-Antagonist Early Effects on Psoriasis: In Vivo Real-time Reflectance Confocal Microscopy and Skin Capacitance Mapping. Journal of Medical Diagnostic Methods, 2015, 04, .	0.0	2

#	ARTICLE	IF	CITATIONS
329	Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2015, 8, 215.	0.8	28
330	Inflammatory Bowel Disease: Pathogenesis, Causative Factors, Issues, Drug Treatment Strategies, and Delivery Approaches. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2015, 32, 181-214.	1.2	38
331	Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 201-209.	0.5	55
332	Expert Recommendations on Treating Psoriasis in Special Circumstances. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2015, 106, 292-309.	0.2	1
333	Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2641-2648.	0.3	116
334	Biologic Agents for Psoriasis. , 2015, , 1411-1420.		0
335	The 5-point Investigatorâ€™s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. <i>Journal of Dermatological Treatment</i> , 2015, 26, 23-31.	1.1	173
336	Interventions for guttate psoriasis. <i>The Cochrane Library</i> , 2015, , .	1.5	2
337	Biosimilars versus originators: similarities and differences from development to approval. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 501-510.	0.3	6
338	Saudi practical guidelines on biologic treatment of psoriasis. <i>Journal of Dermatological Treatment</i> , 2015, 26, 223-229.	1.1	16
339	Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 589-598.	0.6	54
340	Recomendaciones de expertos para el tratamiento de la psoriasis en situaciones especiales. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2015, 106, 292-309.	0.2	9
341	Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the <sc>BELIEVE</sc> study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 353-360.	1.3	75
342	Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases. <i>Pharmacological Reviews</i> , 2015, 67, 280-309.	7.1	266
343	Effectiveness and safety of adalimumab in treating moderate to severe psoriasis patients with psoriatic arthritis in Taiwan. <i>Dermatologica Sinica</i> , 2015, 33, 119-123.	0.2	6
344	Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2015, 172, 1395-1406.	1.4	127
345	Subcutaneous Biological Treatments for Moderate to Severe Psoriasis: Interpreting Safety Data by Network Meta-Analysis. <i>Drugs - Real World Outcomes</i> , 2015, 2, 23-27.	0.7	8
346	Association between Skin and Joint Involvement in Patients with Psoriatic Arthritis Treated with Adalimumab: Analysis of Data from a German Non-Interventional Study. <i>Dermatology</i> , 2015, 230, 213-221.	0.9	4

#	ARTICLE	IF	CITATIONS
347	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 400-409.	0.6	472
348	A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2015, 373, 136-144.	13.9	270
349	Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. <i>Journal of Dermatological Treatment</i> , 2015, 26, 103-112.	1.1	50
350	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and Tj ETQq1 1 0.784314 rgBT / Qv 6.3 7195	6.3	7195
351	Evaluating the economic burden of psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 961-967.e5.	0.6	111
352	Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1576-1581.	1.3	5
353	Biologic Response Modifiers and Pediatric Psoriasis. <i>Pediatric Dermatology</i> , 2015, 32, 303-320.	0.5	18
354	Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic. <i>Journal of Dermatological Treatment</i> , 2015, 26, 493-501.	1.1	21
355	Interleukin-17 Antagonists in the Treatment of Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 109-114.	0.6	13
356	Systemic pharmacological treatments for chronic plaque psoriasis. <i>The Cochrane Library</i> , 0, , .	1.5	8
357	Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 767-776.	1.3	16
358	Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 623-642.	0.8	50
359	Anti-TNF-Î± monoclonal antibody reverses psoriasis through dual inhibition of inflammation and angiogenesis. <i>International Immunopharmacology</i> , 2015, 28, 731-743.	1.7	32
361	Adalimumab: A Review in Chronic Plaque Psoriasis. <i>Drugs</i> , 2015, 75, 2119-2130.	4.9	29
362	Proteomics focusing on immune markers in psoriatic arthritis. <i>Biomarkers in Medicine</i> , 2015, 9, 513-528.	0.6	44
363	Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. <i>British Journal of Dermatology</i> , 2015, 172, 1371-1383.	1.4	179
364	Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel. <i>Journal of Dermatological Treatment</i> , 2015, 26, 128-133.	1.1	14
365	Ten Years On. <i>Dermatologic Clinics</i> , 2015, 33, 111-125.	1.0	18

#	ARTICLE	IF	CITATIONS
366	Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes. <i>Journal of Investigative Dermatology</i> , 2015, 135, 31-38.	0.3	77
367	Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice. <i>Journal of Dermatological Treatment</i> , 2015, 26, 49-53.	1.1	15
368	Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response. <i>British Journal of Dermatology</i> , 2015, 172, 504-512.	1.4	62
370	Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. <i>Acta Dermato-Venereologica</i> , 2016, 96, 251-252.	0.6	21
371	Biologic Therapy in Psoriasis: Safety Profile. <i>Current Drug Safety</i> , 2016, 11, 4-11.	0.3	27
372	Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2016, Volume 9, 347-355.	0.8	11
374	Anti-TNF- α Drugs Differently Affect the TNF- α -sTNFR System and Monocyte Subsets in Patients with Psoriasis. <i>PLoS ONE</i> , 2016, 11, e0167757.	1.1	27
375	Adalimumab: a review of the reference product and biosimilars. <i>Biosimilars (Auckland, New Zealand)</i> , 0, Volume 6, 29-44.	0.4	13
376	Current knowledge on psoriasis and autoimmune diseases. <i>Psoriasis: Targets and Therapy</i> , 2016, 6, 7.	1.2	122
377	Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)- α level and the efficacy of TNF- α inhibitor therapy in psoriasis. <i>Journal of Dermatology</i> , 2016, 43, 1018-1023.	0.6	27
378	Tumour necrosis factor- α plays a significant role in the Aldara-induced skin inflammation in mice. <i>British Journal of Dermatology</i> , 2016, 174, 1011-1021.	1.4	17
379	Clinical, ultrasound, and videodermoscopy monitoring of psoriatic patients following biological treatment. <i>Skin Research and Technology</i> , 2016, 22, 341-348.	0.8	23
380	Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example. <i>RMD Open</i> , 2016, 2, e000154.	1.8	21
381	Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. <i>International Journal of Women's Dermatology</i> , 2016, 2, 151-153.	1.1	12
382	Clinical studies in dermatology require a post-treatment observation phase to define the impact of the intervention on the natural history of the complaint. <i>Archives of Dermatological Research</i> , 2016, 308, 379-387.	1.1	3
383	Review of maintenance of response to psoriasis treatments. <i>Journal of Dermatological Treatment</i> , 2016, 27, 293-297.	1.1	11
384	A Review of Psoriasis, Therapies, and Suicide. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 293-303.	0.6	37
385	Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1584-1591.	0.3	63

#	ARTICLE	IF	CITATIONS
386	Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 612-618.e6.	0.6	48
387	Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris. <i>Dermatology</i> , 2016, 232, 385-406.	0.9	39
388	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. <i>New England Journal of Medicine</i> , 2016, 375, 422-434.	13.9	530
389	A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2016, 174, 1266-1276.	1.4	207
390	HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 989-994.	1.3	137
391	Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 691-699.	3.3	25
392	Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE [®] -PK) in healthy subjects. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1361-1370.	1.9	49
393	Review of Available and Investigational Biologics and Non-Biologic Small Molecules for the Treatment of Plaque Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016, 2, 11-21.	0.3	3
394	Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence. <i>BMJ Open</i> , 2016, 6, e011941.	0.8	10
395	Current status and future prospects for biologic treatments of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1273-1287.	1.3	19
396	Biologic Therapy for Psoriasis. , 2016, , 281-294.		0
397	A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 332-338.	1.1	61
398	Treatment of psoriasis. , 2016, , 43-84.		0
399	Immunopathogenesis of Psoriasis Skin and Nail. , 2016, , 45-52.		0
400	Secukinumab (AIN-457) for the treatment of Psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 187-202.	1.3	10
401	Oral administration of acarbose ameliorates imiquimod-induced psoriasis-like dermatitis in a mouse model. <i>International Immunopharmacology</i> , 2016, 33, 70-82.	1.7	13
402	Persistence and failure rates of adalimumab monotherapy in biologic-naïve patients with psoriasis: A retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 575-577.	0.6	4
403	Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and) <i>TJ ETQq1 1 0.784314.rgBT / Overlock 10</i>		

#	ARTICLE	IF	CITATIONS
404	Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. <i>Rheumatology International</i> , 2016, 36, 603-612.	1.5	54
405	Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review. <i>Journal of Dermatological Treatment</i> , 2016, 27, 406-413.	1.1	26
406	Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 79-86.	3.3	21
407	Anti-interleukin-17 treatment of psoriasis. <i>Journal of Dermatological Treatment</i> , 2016, 27, 311-315.	1.1	12
409	Psoriatic Arthritis and Psoriasis. , 2016, , .		3
410	Ixekizumab: a new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 255-263.	1.4	18
411	Secukinumab for treating plaque psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 119-128.	1.4	18
412	Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. <i>Journal of Dermatological Treatment</i> , 2016, 27, 203-209.	1.1	15
413	Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 304-311.	1.3	34
414	A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 577-593.	1.4	53
415	Short-term efficacy and safety of new biological agents targeting the interleukin-23-T helper 17 pathway for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. <i>British Journal of Dermatology</i> , 2017, 176, 594-603.	1.4	55
416	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 405-417.	0.6	673
417	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 418-431.	0.6	554
418	Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1091-1102.	1.6	29
419	Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled <sc>JUNCTURE</sc> trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 847-856.	1.3	44
420	Efficacy and safety of interleukin-17 antagonists in patients with plaque psoriasis: a meta-analysis from phase 3 randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 992-1003.	1.3	15
421	Evaluation of adherence predictors for the treatment of moderate to severe psoriasis with biologics: the importance of physician-patient interaction and communication. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1014-1020.	1.3	18
422	Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study. <i>Journal of Dermatological Treatment</i> , 2017, 28, 606-612.	1.1	8

#	ARTICLE	IF	CITATIONS
423	Tildrakizumab for treating psoriasis. Expert Opinion on Biological Therapy, 2017, 17, 645-657.	1.4	14
424	Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria. JDDG - Journal of the German Society of Dermatology, 2017, 15, 309-317.	0.4	6
425	Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 774-790.	1.3	140
426	Certolizumab pegol for the treatment of psoriasis. Expert Opinion on Biological Therapy, 2017, 17, 387-394.	1.4	21
427	Etanercept, Adalimumab und Ustekinumab bei Psoriasis: Analyse von 209 Behandlungsreihen in Österreich. JDDG - Journal of the German Society of Dermatology, 2017, 15, 309-318.	0.4	2
428	Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab. British Journal of Dermatology, 2017, 177, 411-418.	1.4	11
429	Switching of biologics in psoriasis: Reasons and results. Journal of Dermatology, 2017, 44, 1015-1019.	0.6	38
430	Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. Journal of Investigative Dermatology, 2017, 137, 1646-1654.	0.3	108
431	Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet, The, 2017, 390, 40-49.	6.3	120
432	Adalimumab in paediatric psoriasis. Lancet, The, 2017, 390, 5-6.	6.3	4
433	TNF Inhibitors for Psoriasis and Psoriatic Arthritis. Current Dermatology Reports, 2017, 6, 113-120.	1.1	1
434	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE) Tj ETQq1 1 0,784314 rgBT / Oe 6.3 428	6.3	428
435	Smad7 positively regulates keratinocyte proliferation in psoriasis. British Journal of Dermatology, 2017, 177, 1633-1643.	1.4	17
436	Drug concentration and antidrug antibodies in patients with psoriasis treated with adalimumab or etanercept. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e518-e519.	1.3	3
437	Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis. British Journal of Dermatology, 2017, 177, 1537-1551.	1.4	43
438	Biologic Therapy in the Treatment of Chronic Skin Disorders. Immunology and Allergy Clinics of North America, 2017, 37, 315-327.	0.7	2
439	Taiwanese Dermatological Association consensus statement on management of psoriasis. Dermatologica Sinica, 2017, 35, 66-77.	0.2	27
440	Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. Journal of the American Academy of Dermatology, 2017, 76, 1093-1102.	0.6	110

#	ARTICLE	IF	CITATIONS
441	Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 70-85.	2.3	7
442	The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 243-249.	1.9	6
443	Should methotrexate remain the first-line drug for psoriasis?. <i>Lancet, The</i> , 2017, 389, 482-483.	6.3	9
444	Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 2S-40S.	0.6	9
445	Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2247-2259.	1.4	87
446	Digestive system in psoriasis: an update. <i>Archives of Dermatological Research</i> , 2017, 309, 679-693.	1.1	38
447	Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 642-648.	2.3	2
448	Certolizumab pegol, ¿un nuevo anti-TNF en el tratamiento de la psoriasis moderada-grave?. <i>Piel</i> , 2017, 32, 644-649.	0.0	0
449	Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis. <i>Journal of Medical Economics</i> , 2017, 20, 1224-1230.	1.0	23
450	Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service. <i>Journal of Dermatological Treatment</i> , 2017, 28, 623-630.	1.1	16
451	Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 75.	2.0	15
452	Antibody and antibody mimetic immunotherapeutics. <i>Future Medicinal Chemistry</i> , 2017, 9, 1301-1304.	1.1	7
453	Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial. <i>BMC Dermatology</i> , 2017, 17, 6.	2.1	15
454	Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Drugs in R and D</i> , 2017, 17, 29-51.	1.1	33
455	Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 89-95.	1.3	75
456	Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2017, 176, 890-901.	1.4	107
457	Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 490-497.	1.3	34
458	Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2017, 176, 1297-1307.	1.4	50

#	ARTICLE	IF	CITATIONS
459	Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. Annual Review of Medicine, 2017, 68, 255-269.	5.0	134
460	Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort. British Journal of Dermatology, 2017, 176, 786-793.	1.4	37
461	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. Journal of the American Academy of Dermatology, 2017, 76, 432-440.e17.	0.6	111
462	Biosimilars for psoriasis: clinical studies to determine similarity. British Journal of Dermatology, 2017, 177, 23-33.	1.4	16
464	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. The Cochrane Library, 2017, 12, CD011535.	1.5	164
465	Unerwünschte Wirkungen von Biologika bei Psoriasis. Karger Kompass Dermatologie, 2017, 5, 195-199.	0.0	1
466	Old and New Biological Therapies for Psoriasis. International Journal of Molecular Sciences, 2017, 18, 2297.	1.8	179
467	Novel carriers and approaches: insight for psoriasis management. , 2017, , 657-684.		1
468	Characterization of skin Th17 transcriptional profiles in psoriatic patients under adalimumab biotherapy. European Journal of Dermatology, 2017, 27, 579-589.	0.3	2
469	Pathogenic Role of Cytokines and Effect of Their Inhibition in Psoriasis. , 0, , .		6
470	Immunosuppressants for the Treatment of Psoriasis. Journal of the Nihon University Medical Association, 2017, 76, 31-35.	0.0	0
471	Guselkumab for the treatment of psoriasis. Expert Opinion on Biological Therapy, 2018, 18, 459-468.	1.4	33
472	Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis. Current Medical Research and Opinion, 2018, 34, 1325-1333.	0.9	27
473	Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification – rationale and design of the randomized, multicenter <scp>STEPI</scp> n study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1930-1939.	1.3	40
474	Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis. Molecular Pain, 2018, 14, 174480691876220.	1.0	12
475	Subcutaneous methotrexate in patients with moderate-to-severe psoriasis: a critical appraisal. British Journal of Dermatology, 2018, 179, 50-53.	1.4	7
476	Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. Journal of the American Academy of Dermatology, 2018, 79, 135-144.e7.	0.6	46
477	Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. American Journal of Clinical Dermatology, 2018, 19, 437-447.	3.3	26

#	ARTICLE	IF	CITATIONS
478	Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. <i>Pharmacology Research and Perspectives</i> , 2018, 6, e00380.	1.1	15
479	Comparison of guidelines for the use of TNF inhibitors for psoriasis in the United States, Canada, Europe and the United Kingdom: a critical appraisal and comprehensive review. <i>Journal of Dermatological Treatment</i> , 2018, 29, 586-592.	1.1	7
480	Programming gene and engineered-cell therapies with synthetic biology. <i>Science</i> , 2018, 359, .	6.0	180
481	Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology and Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients. <i>Current Rheumatology Reports</i> , 2018, 20, 1.	2.1	31
482	Clinical Trial and Registry Data. <i>Current Problems in Dermatology</i> , 2018, 53, 15-27.	0.8	6
483	Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 383-394.	0.6	69
484	The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 557-568.	1.1	35
485	History of Therapies in Dermatology: Past to Present. , 2018, , 1-6.		0
486	Immunogenicity of Biologic Agents in Psoriasis. , 2018, , 93-99.		0
487	Tumor Necrosis Factor Inhibition. , 2018, , 111-121.		0
488	Utilization of Biologic and Systemic Agents in the Elderly. , 2018, , 281-294.		0
489	Incorporating historical information in biosimilar trials: Challenges and a hybrid Bayesian-frequentist approach. <i>Biometrical Journal</i> , 2018, 60, 564-582.	0.6	10
490	Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. <i>JAMA Dermatology</i> , 2018, 154, 581.	2.0	74
491	New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 259-273.	1.3	10
492	Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1297-1304.	1.3	12
493	Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 323-332.	0.6	73
494	Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 403-410.	1.3	37
495	Drug survival of biologic treatments in psoriasis: a systematic review. <i>Journal of Dermatological Treatment</i> , 2018, 29, 460-466.	1.1	66

#	ARTICLE	IF	CITATIONS
496	Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 90-99.e1.	0.6	64
497	Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase 3 VOYAGE 1 and VOYAGE 2 studies. <i>British Journal of Dermatology</i> , 2018, 178, 132-139.	1.4	57
498	Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials. <i>Value in Health</i> , 2018, 21, 1-8.	0.1	18
499	Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. <i>Journal of Dermatological Treatment</i> , 2018, 29, 334-346.	1.1	39
500	Adverse Reactions to Biologics in Psoriasis. <i>Current Problems in Dermatology</i> , 2018, 53, 1-14.	0.8	20
501	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 515-528.	1.3	15
502	Safety of biologics in psoriasis. <i>Journal of Dermatology</i> , 2018, 45, 279-286.	0.6	94
503	Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 405-423.	3.3	72
504	A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 467-474.	1.1	6
505	The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 1-19.	1.3	25
506	Is weekly dose of adalimumab a simple approach for resistant psoriasis?. <i>Journal of Dermatological Treatment</i> , 2018, 29, 233-234.	1.1	1
507	EXISTING AND NOVEL THERAPIES FOR PSORIASIS. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2018, 11, 82.	0.3	2
508	Efeitos adversos do uso de imunobiológicos no tratamento da psoríase. , 2018, 97, 486-492.	0.0	0
509	Cost-effectiveness of apremilast in moderate to severe psoriasis in the United Kingdom. <i>Cogent Medicine</i> , 2018, 5, 1495593.	0.7	4
510	Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 5085-5095.	0.8	16
511	Importance of assessing and adjusting for cross-study heterogeneity in network meta-analysis: a case study of psoriasis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 1037-1051.	0.6	29
512	Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. <i>Journal of Immunology</i> , 2018, 201, 1605-1613.	0.4	388
513	How Long Does the Benefit of Biologics Last? An Update on Time to Relapse and Potential for Rebound of Biologic Agents for Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2018, 3, 65-70.	0.3	2

#	ARTICLE	IF	CITATIONS
514	Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. <i>BioDrugs</i> , 2018, 32, 193-199.	2.2	31
515	Biologics. <i>Updates in Clinical Dermatology</i> , 2018, , 73-92.	0.1	0
516	Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2168-2173.	0.3	41
518	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018, 179, 615-622.	1.4	57
519	Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018, 20, 57.	2.1	53
520	Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. <i>Journal of Dermatology</i> , 2018, 45, 1053-1062.	0.6	85
521	Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. <i>British Journal of Dermatology</i> , 2018, 179, 623-631.	1.4	112
522	Biologic treatment of recalcitrant pediatric psoriasis: a case series from a tertiary medical center. <i>Journal of Dermatological Treatment</i> , 2019, 30, 152-155.	1.1	9
523	Biologics for the primary care physician: Review and treatment of psoriasis. <i>Disease-a-Month</i> , 2019, 65, 51-90.	0.4	62
524	Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 923-930.	0.6	11
525	Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. <i>PLoS ONE</i> , 2019, 14, e0220868.	1.1	118
526	Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase 3, randomized, placebo-controlled trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2168-2178.	1.3	28
527	The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1167-1178.	0.5	152
528	Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis <sc>SOLAPSO</sc> “ Sociedad Latinoamericana de Psoriasis <i>(Latin American Psoriasis) Tj ETQq1 1 0.784304rgBT /Overlock 10		
529	A multicenter retrospective case-control study on Suspension of TNF-inhibitors and Outcomes in Psoriatic patients (STOP study). <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 392-399.	0.8	4
530	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 576-586.	6.3	198
531	<p></p>Therapeutic drug monitoring of biologics in psoriasis<p></p>. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 127-132.	3.0	20
532	Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2437-2446.e1.	0.3	70

#	ARTICLE	IF	CITATIONS
533	Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis. <i>JAMA Dermatology</i> , 2019, 155, 1380.	2.0	5
534	Pharmacodynamics OF TNF $\hat{\pm}$ inhibitors for the treatment of psoriasis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 913-925.	1.5	24
535	Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children. <i>Children</i> , 2019, 6, 108.	0.6	31
536	Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). <i>Seminars in Immunopathology</i> , 2019, 41, 633-644.	2.8	41
537	Risankizumab for the treatment of psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 851-857.	1.3	10
538	Absolute Versus Relative Psoriasis Area and Severity Index in Clinical Practice. <i>Actas Dermo-sifiligrÃ¡ficas</i> , 2019, 110, 606-610.	0.2	3
539	Results of a retrospective study on the efficacy and safety of adalimumab 80Âmg administrated every other week in patients with psoriasis at a single Japanese institution. <i>Journal of Dermatology</i> , 2019, 46, 199-205.	0.6	7
540	An update on clinical safety of adalimumab in treating psoriasis: A systematic review and meta-analysis based on 20 randomized controlled trials. <i>Journal of Cosmetic Dermatology</i> , 2019, 18, 1550-1559.	0.8	2
541	State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. <i>Current Opinion in Pharmacology</i> , 2019, 46, 90-99.	1.7	34
542	Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology. <i>Anais Brasileiros De Dermatologia</i> , 2019, 94, 76-107.	0.5	23
543	TNF- $\hat{\pm}$ inhibitors in the treatment of hidradenitis suppurativa. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231985164.	1.1	33
544	<i>In vitro</i> human helper T-cell assay to screen antibody drug candidates for immunogenicity. <i>Journal of Immunotoxicology</i> , 2019, 16, 125-132.	0.9	13
545	Psoriasis in moderate grave plaque - immunobiological treatment. <i>Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira</i> , 2019, 65, 493-508.	0.3	1
546	Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence. <i>BioDrugs</i> , 2019, 33, 241-253.	2.2	34
547	Use of doseâ€œexposureâ€œresponse relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2082-2086.	1.3	8
548	Recent medical therapy for psoriasis. <i>Journal of the Korean Medical Association</i> , 2019, 62, 176.	0.1	3
549	2018 APLAR axial spondyloarthritis treatment recommendations. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 340-356.	0.9	59
550	Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry. <i>Journal of Dermatology</i> , 2019, 46, 389-398.	0.6	25

#	ARTICLE	IF	CITATIONS
551	Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis. <i>Journal of Pharmacological Sciences</i> , 2019, 139, 289-303.	1.1	26
552	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2120-2130.	1.5	128
553	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1029-1072.	0.6	542
554	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1073-1113.	0.6	281
555	Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis. <i>The Cochrane Library</i> , 2019, 2019, CD011541.	1.5	6
556	Risankizumab in moderate-to-severe plaque psoriasis. <i>Immunotherapy</i> , 2019, 11, 1357-1370.	1.0	5
557	Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2019, 180, 76-85.	1.4	23
558	Pharmacotherapeutic strategies for standard treatment-resistant psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 443-454.	0.9	14
559	Psoriasis y depresi3n: el papel de la inflamaci3n. <i>Actas Dermo-sifiliogr3ficas</i> , 2019, 110, 12-19.	0.2	43
560	Psoriasis and Depression: The Role of Inflammation. <i>Actas Dermo-sifiliogr3ficas</i> , 2019, 110, 12-19.	0.2	29
561	Tildrakizumab for the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 5-12.	1.3	19
562	Biologics and Psoriasis. <i>Dermatologic Clinics</i> , 2019, 37, 29-36.	1.0	43
563	Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 81-92.	0.3	18
564	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 251-265.e19.	0.6	362
565	Review of safety and efficacy of approved systemic psoriasis therapies. <i>International Journal of Dermatology</i> , 2019, 58, 649-658.	0.5	66
566	Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label <sc>OPTIMISE</sc> study. <i>British Journal of Dermatology</i> , 2020, 182, 304-315.	1.4	33
567	<sc>AURIEL</sc> 3PsO: a randomized, double-blind phase <sc>III</sc> equivalence trial to demonstrate the clinical similarity of the proposed biosimilar <sc>MSB</sc> 11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2020, 182, 316-326.	1.4	41
568	Psoriatic arthritis for dermatologists. <i>Journal of Dermatological Treatment</i> , 2020, 31, 662-679.	1.1	52

#	ARTICLE	IF	CITATIONS
569	US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2020, 31, 333-341.	1.1	23
570	Biologics for chronic inflammatory skin diseases: an update for the clinician. <i>Journal of Dermatological Treatment</i> , 2020, 31, 108-130.	1.1	17
571	The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study. <i>Journal of Dermatological Treatment</i> , 2020, 31, 213-221.	1.1	13
572	Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 412-424.	0.6	12
574	Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Therapeutics Update). <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 577-580.	1.0	50
575	Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses. <i>Dermatology and Therapy</i> , 2020, 10, 73-86.	1.4	38
576	Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 435-442.	2.3	14
577	Japanese guidance for use of biologics for psoriasis (the 2019 version). <i>Journal of Dermatology</i> , 2020, 47, 201-222.	0.6	58
578	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 1, CD011535.	1.5	86
579	Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1138-1149.	0.6	37
580	Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1015-1025.e4.	0.3	12
581	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945.	0.6	71
582	Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. <i>Advances in Therapy</i> , 2020, 37, 364-380.	1.3	51
583	Association of previous treatment with anti-tumour necrosis factor inhibitors with the effectiveness of secukinumab in the treatment of psoriatic arthritis: systematic review and meta-analysis. <i>Rheumatology</i> , 2020, 59, 3657-3665.	0.9	2
584	Retrospective analysis of patients with psoriasis receiving biological therapy: Real-life data. <i>Dermatologic Therapy</i> , 2020, 33, e14336.	0.8	5
586	Fetal Acrania (Exencephaly) in the Context of a Pregnant Female Taking Adalimumab for Psoriasis: A Case Report. <i>Biologics: Targets and Therapy</i> , 2020, Volume 14, 127-129.	3.0	2
587	Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8436.	1.8	32
588	Severe Acute Respiratory Syndrome Coronavirus 2 and the Use of Biologics in Patients With Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 625-632.	0.6	5

#	ARTICLE	IF	CITATIONS
589	Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. <i>Advances in Therapy</i> , 2020, 37, 3732-3745.	1.3	11
590	Chinese Experts Consensus on Biologic Therapy for Psoriasis#. <i>International Journal of Dermatology and Venereology</i> , 2020, 3, 76-85.	0.1	1
591	The TNF/IL-23/IL-17 axis as a "Head-to-head" trials comparing different biologics in psoriasis treatment. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12946.	1.3	58
592	Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. <i>Dermatology</i> , 2021, 237, 158-165.	0.9	3
593	Association of Pathogenic Th17 Cells with the Disease Severity and Its Potential Implication for Biological Treatment Selection in Psoriasis Patients. <i>Mediators of Inflammation</i> , 2020, 2020, 1-16.	1.4	12
594	Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis. <i>Chinese Medical Journal</i> , 2020, 133, 2665-2673.	0.9	24
595	Tapering and discontinuation of systemic medications in psoriasis patients with low disease activity. <i>Dermatologic Therapy</i> , 2020, 33, e13599.	0.8	7
596	Pathophysiology, Clinical Presentation, and Treatment of Psoriasis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1945.	3.8	953
597	Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days. <i>Dermatologic Therapy</i> , 2020, 33, e13686.	0.8	9
598	Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. <i>Dermatologic Therapy</i> , 2020, 33, e13687.	0.8	45
599	Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 737-750.	0.6	3
600	Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 211-232.	1.3	12
601	Emerging systemic drugs in the treatment of plaque psoriasis. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 89-100.	1.0	23
602	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 431-447.	1.4	40
603	Efficacy and safety of adalimumab 80 mg in the treatment of psoriasis: a bicentric retrospective study. <i>Dermatologic Therapy</i> , 2020, 33, e13369.	0.8	0
604	COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement. <i>Australasian Journal of Dermatology</i> , 2020, 61, 210-216.	0.4	43
605	Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 561-572.	0.6	5
606	Recent advances in the management of non-infectious posterior uveitis. <i>International Ophthalmology</i> , 2020, 40, 3187-3207.	0.6	7

#	ARTICLE	IF	CITATIONS
607	Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration. <i>International Journal of Dermatology</i> , 2020, 59, 1043-1056.	0.5	19
608	Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2020, 32, 1-9.	1.1	1
609	In psoriasis treatment, greater improvement in skin severity predicts greater improvement in nail severity. <i>Journal of Dermatological Treatment</i> , 2020, 32, 1-4.	1.1	3
610	Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times. <i>Dermatology and Therapy</i> , 2020, 10, 339-349.	1.4	37
611	Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 135-142.	1.3	29
612	Toward a tailored therapeutic prescription for patients with axial spondyloarthritis. <i>Joint Bone Spine</i> , 2021, 88, 105019.	0.8	10
613	Intermittent use of biologic agents for the treatment of psoriasis in adults. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 360-367.	1.3	14
614	Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review. <i>Dermatologic Therapy</i> , 2021, 34, e14498.	0.8	20
615	Axial psoriatic arthritis: An update for dermatologists. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 92-101.	0.6	41
616	Tumor Necrosis Factor Inhibitors. , 2021, , 287-301.e7.		2
617	Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 329-337.	1.3	13
618	Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 87-96.	1.4	12
619	Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. <i>Journal of Dermatological Treatment</i> , 2021, 32, 302-309.	1.1	11
620	The Role of Leptin in the Association between Obesity and Psoriasis. <i>Biomolecules and Therapeutics</i> , 2021, 29, 11-21.	1.1	26
621	Immunogenicity to biological drugs in psoriasis and psoriatic arthritis. <i>Clinics</i> , 2021, 76, e3015.	0.6	9
622	Psoriasis: Recent progress in molecular-targeted therapies. <i>Journal of Dermatology</i> , 2021, 48, 761-777.	0.6	39
623	PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1661-1669.	1.1	15
624	Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values 1, 2, 3 or 5 derived from a statistical conversion method. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1161-1175.	1.3	13

#	ARTICLE	IF	CITATIONS
625	Certolizumab pegol in the treatment of psoriasis: <sc>Real-life</sc> data. <i>Dermatologic Therapy</i> , 2021, 34, e14929.	0.8	6
626	Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. <i>Dermatology and Therapy</i> , 2021, 11, 885-905.	1.4	40
627	Effect of adalimumab interventions on general infection among adults: a systematic review and meta-analysis of randomized controlled trials. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1281-1297.	2.0	1
628	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD011535.	1.5	34
629	Psoriasis. <i>Lancet</i> , The, 2021, 397, 1301-1315.	6.3	792
631	Immunogenicity of biologics used in the treatment of moderate to severe psoriasis. <i>Human Antibodies</i> , 2021, 29, 1-8.	0.6	1
632	Biological anti-psoriatic therapy profoundly affects high-density lipoprotein function. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 158943.	1.2	4
633	An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2987-2998.	2.0	8
634	Saudi consensus statement on biologic treatment of chronic plaque psoriasis (2020). <i>Journal of Dermatological Treatment</i> , 2021, , 1-15.	1.1	1
635	Direct comparison of risankizumab and fumaric acid esters in systemic therapy – naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2022, 186, 30-39.	1.4	9
636	Potential Treatment of Psoriasis with Oral Spironolactone as TNF-Alpha Inhibitor – A Future Prospective Review. <i>Shanghai Ligong Daxue Xuebao/Journal of University of Shanghai for Science and Technology</i> , 2021, 23, 411-420.	0.1	0
637	A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. <i>Frontiers in Medicine</i> , 2021, 8, 702776.	1.2	9
638	Biologics modulate antinuclear antibodies, immunoglobulin E, and eosinophil counts in psoriasis patients. <i>Journal of Dermatology</i> , 2021, 48, 1739-1744.	0.6	8
639	Enhanced NF- κ B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. <i>Nature Communications</i> , 2021, 12, 4741.	5.8	23
640	Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 572-581.	0.6	36
641	Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2021, 11, 1965-1998.	1.4	14
642	New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2328-2337.	0.3	21
644	A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains. <i>Frontiers in Medicine</i> , 2020, 7, 618163.	1.2	14

#	ARTICLE	IF	CITATIONS
645	Comparison of Biologics and Oral Treatments for Plaque Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 258.	2.0	169
647	PASI absoluto versus PASI relativo en la prÁctica clÁnica real. <i>Actas Dermo-sifiliogrÁficas</i> , 2019, 110, 606-610.	0.2	4
648	A Brief History of Psoriasis Management in Canada. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 273-277.	0.6	1
649	Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, 91-97.	1.6	18
650	Biological therapies in psoriasis - revisited. <i>Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne</i> , 2018, 56, 75-84.	0.3	4
651	Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2010, 3, 49.	0.8	3
652	Therapeutic Antibodies by Phage Display. <i>Current Pharmaceutical Design</i> , 2017, 22, 6538-6559.	0.9	27
653	A Mechanism-Based Classification of Dermatologic Reactions to Biologic Agents Used in the Treatment of Cutaneous Disease: Part 2. <i>Dermatitis</i> , 2009, 20, 243-256.	0.8	13
654	Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2017, 21, 1-244.	1.3	16
655	Biological therapy of psoriasis. <i>Indian Journal of Dermatology</i> , 2010, 55, 161.	0.1	36
656	A case of subacute thyroiditis in a patient on adalimumab for treatment of refractory palmo-plantar psoriasis. <i>Muller Journal of Medical Sciences and Research</i> , 2014, 5, 70.	0.0	4
657	Apremilast coadministered with secukinumab for safe and effective control of psoriasis with resultant reduction of maintenance dose of the biologic. <i>Indian Journal of Dermatology</i> , 2019, 64, 239.	0.1	3
658	The use of biologics for severe psoriasis. <i>Journal of the Korean Medical Association</i> , 2015, 58, 917.	0.1	3
660	The Effect of TNF-Î± Inhibitors on Nail Psoriasis and Psoriatic Arthritisâ€”Real-World Data from Dermatology Practice. <i>Journal of Personalized Medicine</i> , 2021, 11, 1083.	1.1	0
661	Adalimumab for the treatment of psoriasis. <i>Expert Review of Dermatology</i> , 2009, 4, 15-21.	0.3	1
665	NORMAS DE BOA PRÁTICA PARA O TRATAMENTO DA PSORÍASE EM PLACAS EM IDADE NÃO PEDIÁTRICA COM BIOLÓGICOS. <i>Journal of the Portuguese Society of Dermatology and Venereology</i> , 2011, 69, 532.	0.0	2
666	Biotech on the Rise: The Treatment of Psoriasis with Biological Drugs. , 0, , .		0
667	IL-17A as a Therapeutic Target for Autoimmune Diseases. , 2013, , 333-347.		0

#	ARTICLE	IF	CITATIONS
669	History of Psoriasis. , 2014, , 1-7.		2
671	Algorithm for Selecting Ideal Biologic Treatment for Psoriasis. Journal of Clinical & Experimental Dermatology Research, 2015, 06, .	0.1	0
672	Biologics in the Treatment of Plaque Psoriasis: Drug Selection by Means of the SOJA Method. Journal of Pharmaceutical Care & Health Systems, 2016, 1, .	0.1	0
673	69-Year-Old with Psoriasis and a History of Skin Cancer. , 2017, , 117-126.		0
674	43-Year-Old with Recurrence of Red, Scaly Rash. , 2017, , 95-103.		0
676	Dermatology Free from Ointments. Research in Medical & Engineering Sciences, 2019, 7, .	0.0	0
678	Scalp Psoriasis. , 2020, , 177-195.		1
679	Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multipleâ€treatments metaâ€analysis. JDDG - Journal of the German Society of Dermatology, 2021, 19, 47-56.	0.4	12
680	Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern. Dermatology, 2021, 237, 759-768.	0.9	3
681	Systemic Drugs Used inÂDermatology. , 2020, , 177-212.		0
682	Viva voce: Adalimumab. Indian Journal of Drugs in Dermatology, 2020, 6, 53.	0.0	0
683	How current biologic therapies affect the risk of major adverse cardiovascular events in patients with plaque psoriasis? A systematic review and meta-analysis of randomized controlled trials. Postepy Dermatologii i Alergologii, 2020, 37, 986-994.	0.4	2
684	Guidelines for the Diagnosis and Treatment of Psoriasis in China: 2019 Concise Edition#. International Journal of Dermatology and Venereology, 2020, 3, 14-26.	0.1	4
685	Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a realâ€world setting. British Journal of Dermatology, 2022, 186, 726-728.	1.4	3
686	Realâ€world, longâ€term treatment patterns of commonly used biologics in Canadian patients with moderateâ€toâ€severe chronic plaque psoriasis. Journal of Dermatology, 2022, 49, 95-105.	0.6	11
687	Evolution of immunotherapy methods for psoriasis and psoriatic arthritis: from total immunosuppression to selective treatment of therapeutic targets. Medical Alphabet, 2020, , 15-21.	0.0	0
689	Adalimumab for Psoriasis. , 2021, , 153-172.		0
690	Immunomodulators in the Treatment of Psoriasis. Journal of Drug Delivery and Therapeutics, 2020, 10, 213-215.	0.2	0

#	ARTICLE	IF	CITATIONS
691	Systemic treatment of psoriasis: from methotrexate to biologics. <i>Vestnik Dermatologii i Venerologii</i> , 2020, 96, 7-26.	0.2	6
692	Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. <i>Biologics: Targets and Therapy</i> , 2009, 3, 303-18.	3.0	19
693	How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis. <i>Psoriasis Forum</i> , 2010, 16, 36-42.	0.1	9
694	Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2014, 7, 16-24.	0.1	24
695	Biologic safety in psoriasis: review of long-term safety data. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2015, 8, 30-42.	0.1	11
696	Biological therapies in moderate and severe psoriasis: perspectives and certainties. <i>Journal of Medicine and Life</i> , 2014, 7 Spec No. 2, 15-7.	0.4	0
697	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, S5-S29.	0.1	2
698	Psoriasis and Psoriatic Arthritis. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2017, 10, S16-S25.	0.1	3
699	Effect of Adalimumab on Gene Expression Profiles of Psoriatic Skin and Blood. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 988-94.	0.4	6
700	Current Developments in the Immunology of Psoriasis. <i>Yale Journal of Biology and Medicine</i> , 2020, 93, 97-110.	0.2	56
701	Real-life Efficacy and Safety of Biosimilar Adalimumab (ZRC-3197) in Patients with Plaque Psoriasis: A Tertiary Care Center Experience. <i>Indian Dermatology Online Journal</i> , 2020, 11, 182-186.	0.2	0
702	Plaque-type psoriasis inhibitors. <i>International Immunopharmacology</i> , 2021, 101, 108326.	1.7	6
703	Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study. <i>Advances in Therapy</i> , 2022, 39, 583-597.	1.3	4
704	N6-methyladenosine-modified long non-coding RNA AGAP2-AS1 promotes psoriasis pathogenesis via miR-424-5p/AKT3 axis. <i>Journal of Dermatological Science</i> , 2022, 105, 27-36.	1.0	11
705	Real-life efficacy and safety of biosimilar adalimumab (ZRC-3197) in patients with plaque psoriasis: A tertiary care center experience. <i>Indian Dermatology Online Journal</i> , 2020, 11, 182.	0.2	1
706	IL-23 blockers in dermatology. <i>Indian Journal of Drugs in Dermatology</i> , 2021, 7, 51.	0.0	0
707	Canadian Adalimumab Post-Marketing Observational Epidemiological Study Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-Month Results of Comparative Effectiveness of Adalimumab and nbDMARDs. <i>Journal of Rheumatology</i> , 2022, , jrheum.200609.	1.0	0
708	Racial/ethnic differences in treatment efficacy and safety for moderate-to-severe plaque psoriasis: a systematic review. <i>Archives of Dermatological Research</i> , 2023, 315, 41-50.	1.1	7

#	ARTICLE	IF	CITATIONS
709	Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management. Psoriasis: Targets and Therapy, 2022, Volume 12, 1-14.	1.2	7
710	Update on the etiopathogenesis of psoriasis (Review). Experimental and Therapeutic Medicine, 2022, 23, 201.	0.8	22
712	Choosing the right biologic for complications of inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2022, 16, 235-249.	1.4	3
713	No Evidence that Variations in Ambient Solar Ultraviolet Radiation and Psoriasis Severity are Associated. Journal of Psoriasis and Psoriatic Arthritis, 0, , 247553032210798.	0.3	1
714	A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST). Expert Opinion on Investigational Drugs, 2022, 31, 965-976.	1.9	8
715	An update on the adalimumab biosimilar landscape following approval of the first high-concentration biosimilar. Immunotherapy, 2022, 14, 235-252.	1.0	2
716	Systemic Treatments for Adult Patients with Moderate-to-Severe Psoriasis: Consensus Statements for the United Arab Emirates. Emirates Medical Journal, 2022, 3, 17-34.	0.3	0
717	Immune mechanisms of psoriasis. New strategies of biotherapy. Vestnik Dermatologii I Venerologii, 2010, 86, 35-47.	0.2	11
718	Pharmacoeconomic aspects of treatment of psoriasis with biological drugs. Vestnik Dermatologii I Venerologii, 2012, 88, 26-31.	0.2	1
719	What Can IBD Specialists Learn from IL-23 Trials in Dermatology?. Journal of Crohn's and Colitis, 2022, 16, ii20-ii29.	0.6	10
720	[Translated article] Practical Update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis With Biologic Therapy. Actas Dermo-sifilograficas, 2022, 113, T261-T277.	0.2	4
721	Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial. PLoS ONE, 2022, 17, e0263214.	1.1	2
723	Clinical and economic analysis of administering ustekinumab(stelara) to patients with severe psoriasis. Vestnik Dermatologii I Venerologii, 2011, 87, 63-70.	0.2	0
724	Search for new molecular targets for anticytokine therapy of patients, suffering from the immune dependent skin disease " psoriasis. Vestnik Dermatologii I Venerologii, 2012, 88, 24-34.	0.2	0
725	Drug survival of biologic agents in patients with psoriatic arthritis from a medical center in southern Taiwan. Dermatologica Sinica, 2022, 40, 20.	0.2	4
727	Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis. Advances in Therapy, 2022, 39, 2256-2269.	1.3	10
728	Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis. Pharmaceutics, 2022, 14, 654.	2.0	9
729	Immunobiologics in dermatology. Anais Brasileiros De Dermatologia, 2022, , .	0.5	1

#	ARTICLE	IF	CITATIONS
730	The Relapse of Psoriasis: Mechanisms and Mysteries. <i>JID Innovations</i> , 2022, 2, 100116.	1.2	37
731	Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?. <i>EMJ Dermatology</i> , 0, , 106-121.	0.0	1
732	Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis. <i>Chinese Medical Journal</i> , 2022, 135, 11-19.	0.9	4
734	The Role of Helper T Cells in Psoriasis. <i>Frontiers in Immunology</i> , 2021, 12, 788940.	2.2	70
735	A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 106-110.	0.1	0
736	Short-term effect and safety of a new generation of monoclonal antibodies targeting interleukin-23p19 for treatment of psoriasis: a systematic review and meta-analysis. <i>European Journal of Dermatology</i> , 2019, 29, 302-314.	0.3	2
737	Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. <i>Biologics: Targets and Therapy</i> , 2009, 3, 303.	3.0	9
738	Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases. <i>Science Advances</i> , 2022, 8, eabn4776.	4.7	15
739	Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 433-447.	3.3	17
740	Treatment algorithms for special cases. <i>Turkderm</i> , 0, , 80-85.	0.0	0
742	Tumor necrosis factor (TNF) inhibitors. , 2013, , 307-318.e4.		1
743	Personalization of an anti-cytokine therapy of psoriatic patients. <i>Vestnik Dermatologii i Venerologii</i> , 2015, 91, 54-61.	0.2	1
744	Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	25
746	Association Between Short-Term PASI90 Achievement and Drug Survival of Biologics in Patients with Psoriasis. <i>Annals of Dermatology</i> , 2022, 34, 173.	0.3	2
747	4â€fThe psoriasiform reaction pattern. , 2010, , 49-67.		0
748	Infection risk in psoriatic patients receiving tumour necrosis factor inhibitors: a 20â€year systematic review and metaâ€analysis of randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2301-2315.	1.3	1
749	The impact of the first COVID-19 wave on office-based dermatological care in Germany: a focus on diagnosis, therapy and prescription of biologics. <i>European Journal of Dermatology</i> , 2022, 32, 195-206.	0.3	1
750	Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study. <i>Dermatology and Therapy</i> , 0, , .	1.4	2

#	ARTICLE	IF	CITATIONS
751	Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. , 0, , .		0
752	Risk of Candida Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Clinical Practice, 2022, 2022, 1-11.	0.8	5
753	Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis. Frontiers in Medicine, 0, 9, .	1.2	5
754	Early intervention and disease memory in psoriasis: A literature review. , 2022, 1, 307-316.		5
755	Increasing to weekly adalimumab dosing leads to improved psoriasis outcomesâ€”A retrospective single-centre review of real-world data. Journal of the European Academy of Dermatology and Venereology, 2023, 37, .	1.3	1
756	Pathogenesis, multi-omics research, and clinical treatment of psoriasis. Journal of Autoimmunity, 2022, 133, 102916.	3.0	21
758	Anti-IL 23 biologics for the treatment of plaque psoriasis. Expert Opinion on Biological Therapy, 2022, 22, 1489-1502.	1.4	7
760	Current and emerging biologic and small molecule systemic treatment options for psoriasis and psoriatic arthritis. Current Opinion in Pharmacology, 2022, 67, 102292.	1.7	4
761	Letter to the Editor: Does Ambient Ultraviolet Radiation Affect Psoriasis Severity. Journal of Psoriasis and Psoriatic Arthritis, 0, , 247553032211312.	0.3	0
762	Pathways to Silencing Psoriasis: Remission or Cure?. EMJ Dermatology, 0, , 2-8.	0.0	0
764	Development of therapeutic antibodies for the treatment of diseases. Molecular Biomedicine, 2022, 3, .	1.7	19
765	Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China. Dermatology and Therapy, 0, , .	1.4	1
766	Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis. Life, 2022, 12, 2075.	1.1	1
767	Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the <scp>STEPIn</scp> study. Journal of the European Academy of Dermatology and Venereology, 2023, 37, 1004-1016.	1.3	5
768	English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). Journal of Dermatology, 2023, 50, .	0.6	12
769	Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review. Seminars in Arthritis and Rheumatism, 2023, 59, 152165.	1.6	3
770	ANALYSIS OF THE EFFICACY AND SAFETY OF GENETICALLY ENGINEERED BIOLOGICAL THERAPY FOR MODERATELY SEVERE AND SEVERE FORMS OF PSORIASIS. , 2022, 19, 3-9.		0
771	Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: A systematic review and aggregate data meta-analysis of randomized controlled trials. International Journal of Rheumatic Diseases, 2023, 26, 625-637.	0.9	4

#	ARTICLE	IF	CITATIONS
772	Identification of novel immune subtypes and potential hub genes of patients with psoriasis. Journal of Translational Medicine, 2023, 21, .	1.8	0
773	Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA. Dermatology and Therapy, 2023, 13, 1053-1068.	1.4	3
774	Real-World Drug Survival of Patients with Hidradenitis Suppurative Treated with Adalimumab. JAAD International, 2023, , .	1.1	0
775	Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy. Journal of Dermatological Treatment, 2023, 34, .	1.1	4
787	Biologic Agents for Psoriasis. , 2023, , 1595-1606.		0
791	Signaling pathways and targeted therapies for psoriasis. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	6